Atara Biotherapeutics to Present at Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 24, 2017 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the Company will present at three upcoming investor conferences in June:

  • Jefferies 2017 Global Healthcare Conference
    • Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will present a corporate overview on Tuesday, June 6, 2017 at 3:30 p.m. ET. The conference will be held at the Grand Hyatt Hotel in New York, NY.
  • Goldman Sachs 38th Annual Global Healthcare Conference
    • Chris Haqq, M.D., Ph.D., the Company’s Executive Vice President of Research and Development and Chief Scientific Officer, will participate in a fireside chat discussion on Tuesday, June 13, 2017 at 4:00 p.m. PT. The conference will be held at the Terranea Resort in Rancho Palos Verdes, CA.
  • JMP Securities 2017 Life Sciences Conference
    • John Craighead, Ph.D., the Company’s Vice President of Investor Relations and Corporate Communications, will participate in a panel discussion entitled “Immuno-oncology: From the Lab to the Clinic” on Wednesday, June 21, 2017 at 11:00 a.m. ET. The Conference will be held at the St. Regis Hotel in New York, NY.

Live webcasts of the presentations at the Jefferies and Goldman Sachs healthcare conferences will be available by visiting the Investors section of the Atara Bio website at Archived replays of the webcasts will be available on the Company’s website for 14 days following each presentation.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biotechnology company developing T-cell immunotherapies for patients with severe and life-threatening diseases who have been underserved by scientific innovation, with a focus on cancer and autoimmune and infectious diseases.  Atara’s “Off-the-Shelf” allogeneic T-cell immunotherapy platform harnesses the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses.  Atara’s most advanced product candidate, ATA129, for cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disease (EBV-PTLD) and other EBV positive solid tumors is expected to enter Phase 3 clinical studies in 2017.  The company’s clinical stage pipeline also includes cytotoxic T-cells (CTL) targeting Wilms Tumor 1 (WT1), or ATA520, and Cytomegalovirus (CMV), or ATA230.  Atara’s next generation T-cell immunotherapy for autoimmune disease is an EBV-specific CTL product candidate, or ATA188, that selectively targets specific antigens of EBV believed to be important for the potential treatment of multiple sclerosis (MS).


John Craighead, Atara Biotherapeutics

Steve Klass, Burns McClellan
212-213-0006 x331

Justin Jackson, Burns McClellan
212-213-0006 x327